Recent patent applications in biomarkers

Patent number	Description	Assignee	Inventor	Priority application date	Publication date
WO 2011035433	A method of screening for, diagnosing or detecting lung cancer in a subject that involves determining a level of one or more biomarkers in a sample from the subject and comparing the level of each biomarker to that in a control.	University Health Network (Toronto, ON, Canada)	Diamandis EP, Planque C	9/23/2009	3/31/2011
WO 2011035012	Determining whether a congestive heart failure patient will respond to a pharmacotherapy treatment, comprising determining the expression level of at least ten selected biomarker genes from a biological sample obtained from a congestive heart failure patient.	Regents of the University of Colorado (Denver, CO, USA)	Lowes BD	9/16/2009	3/24/2011
WO 2011035083	A method of predicting which patients will respond to apoptosis proteins–inhibiting compound, involving administering apoptosis proteins inhibitor compound to a patient and measuring specific tumor necrosis factor levels.	Novartis (Basel, Switzerland)	Firestone BG, Levine K, Porter DA, Sullivan J, Zawel L	9/18/2009	3/24/2011
WO 2011034596	A high-throughput method for quantifying the staining of a biomarker in an original image of a pathology sample to detect a disease condition (e.g., ovarian cancer) involving biomarker segmentation using hierarchical normalized cuts.	Rutgers University (New Brunswick, NJ, USA), Chandran S, Janowczyk A, Madabhushi A	Chandran S, Janowczyk A, Madabhushi A	9/18/2009	3/24/2011
WO 2011032155	Detection of a neurological condition (e.g., stroke) comprising measuring the quantity of neuron-specific biomarker in a sample, where the synthesis of the biomarker is altered following an injury, and detecting the condition based on a ratio of the quantity of the biomarker in the biological sample.	Banyan Biomarkers (Alachua, FL, USA)	Hayes RL, Liu MC, Wang KK, Zhang Z	9/14/2009	3/17/2011
DE 202010009743	Biomarker for determining fatty acid chromatography, spectroscopy, chemical analysis, enzymatic or immunological diagnosis, or total fat content or content of synthesized fatty acids used over hair components.	Agricon (Rostock, Germany)	—	7/1/2010	3/17/2011
WO 2011031344	Diagnosing whether an individual does or does not have cancer, comprising detecting biomarker values in a biological sample (e.g., serum) and classifying the individual as having or not having cancer based on biomarker values.	SomaLogic (Boulder, CO, USA)	Brody EN, Gold L, Mehan M, Messenbaugh M, Nikrad M, Ostroff RM, Schwartz RS, Stewart AAE, Walker J, Williams SA, Zichi D	9/9/2009	3/17/2011
WO 2011032109	Predicting a level of severity or disease progression of spinal muscular atrophy in a patient, involving measuring levels or ratio of specific markers in a biological sample and comparing the measured levels or ratio to reference values.	SMA Foundation (New York)	Chen K, Forrest S, Joyce C, Kobayshi D	9/11/2009	3/17/2011
WO 2011028660	A biomarker of decitabine-sensitive cancer stem cells comprising DNA methyltransferase 3B; useful for treating chemotherapeutic drug–resistant cancer.	Dartmouth College (Hanover, NH, USA)	Beyrouthy MJ, Spinella M	9/1/2009	3/10/2011
US 20110024630, WO 2011016890	A device for monitoring infrared observable changes in live cells in real time, comprising a growth-supporting environment that defines an enclosure vessel that includes an attenuated total reflectance substrate comprised of a preselected material.	Battelle Memorial Institute (Richland, WA, USA)	Addleman RS, Riley BJ, Sacksteder CA, Sundaram SK, Weber TJ	7/29/2009	2/3/2011, 2/10/2011

Source: Thomson Scientific Search Service. The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1800 Diagonal Road, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) 337-9368 (http://www.thomson.com/scientific).